Evaluation of the neuroprotective effect of antipsychotics by serum quantification of protein S100B
Open Access
- 21 June 2024
- journal article
- research article
- Published by Elsevier in Farmacia Hospitalaria
- Vol. 49 (2) , 94-98
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Neuroapoptosis in newborns with respiratory acidosis at birthClinical Biochemistry, 2019
- Sedation with midazolam without neurotoxic effectsMedicina Clínica (English Edition), 2018
- Efecto neuroprotector del sevoflurano en anestesia generalMedicina Clinica, 2017
- Higher Plasma S100B Concentrations in Schizophrenia Patients and Dependently Associated with Inflammatory MarkersScientific Reports, 2016
- The Atypical Antipsychotic Agent, Clozapine, Protects Against Corticosterone-Induced Death of PC12 Cells by Regulating the Akt/FoxO3a Signaling PathwayMolecular Neurobiology, 2016
- Daño cerebral postanestesia generalMedicina Clinica, 2016
- Validez del factor cognitivo de la PANSS como medida del rendimiento cognitivo en esquizofreniaRevista de Psiquiatría y Salud Mental, 2009
- Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia — Original research and meta-analysisPsychiatry Research, 2009
- S100B is expressed in, and released from, OLN-93 oligodendrocytes: Influence of serum and glucose deprivationNeuroscience, 2008
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987